Cargando…

Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases

Prostate cancer (PCa) is the second-most common cause of male cancer-related death in western industrialized countries, and the emergence of metastases is a key challenge in the treatment of PCa. Accumulating studies have shown that long noncoding RNAs (lncRNAs) play an important role in the regulat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sattari, Mina, Kohvakka, Annika, Moradi, Elaheh, Rauhala, Hanna, Urhonen, Henna, Isaacs, William B, Nykter, Matti, Murtola, Teemu J, Tammela, Teuvo L J, Latonen, Leena, Bova, G Steven, Kesseli, Juha, Visakorpi, Tapio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326635/ https://www.ncbi.nlm.nih.gov/pubmed/37140987 http://dx.doi.org/10.1530/ERC-22-0247

Ejemplares similares

Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen
por: Kukkonen, Konsta, et al.
Publicado: (2022)

Epigenetically altered miR-193b targets cyclin D1 in prostate cancer
por: Kaukoniemi, Kirsi M, et al.
Publicado: (2015)

Expression and ERG regulation of PIM kinases in prostate cancer
por: Eerola, Sini K., et al.
Publicado: (2021)

Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation
por: Nätkin, Reetta, et al.
Publicado: (2023)

Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression
por: Latonen, Leena, et al.
Publicado: (2018)

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
por: Kallio, Heini M. L., et al.
Publicado: (2018)

Proteomics of prostate cancer – revealing how cancer cells master their messy genomes
por: Latonen, Leena, et al.
Publicado: (2018)

The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017)

Feature-based analysis of mouse prostatic intraepithelial neoplasia in histological tissue sections
por: Ruusuvuori, Pekka, et al.
Publicado: (2016)

Comparative analysis of tissue reconstruction algorithms for 3D histology
por: Kartasalo, Kimmo, et al.
Publicado: (2018)

Analysis of spatial heterogeneity in normal epithelium and preneoplastic alterations in mouse prostate tumor models
por: Valkonen, Mira, et al.
Publicado: (2017)

Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer
por: Sjöblom, Liisa, et al.
Publicado: (2016)

Spatial analysis of histology in 3D: quantification and visualization of organ and tumor level tissue environment
por: Ruusuvuori, Pekka, et al.
Publicado: (2022)

Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine
por: Nurminen, Anssi, et al.
Publicado: (2023)

Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer
por: Annala, Matti, et al.
Publicado: (2015)

Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer
por: Bova, G. Steven, et al.
Publicado: (2016)

Overall and worst gleason scores are equally good predictors of prostate cancer progression
por: Tolonen, Teemu T, et al.
Publicado: (2011)

Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas
por: Lehtinen, Birgitta, et al.
Publicado: (2017)

Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas
por: Granberg, Kirsi J, et al.
Publicado: (2017)

Contribution of ARLTS1 Cys148Arg (T442C) Variant with Prostate Cancer Risk and ARLTS1 Function in Prostate Cancer Cells
por: Siltanen, Sanna, et al.
Publicado: (2011)

Balance between Noise and Information Flow Maximizes Set Complexity of Network Dynamics
por: Mäki-Marttunen, Tuomo, et al.
Publicado: (2013)

Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial
por: Veitonmäki, Thea, et al.
Publicado: (2016)

Mapping of the chromosomal amplification 1p21-22 in bladder cancer
por: Scaravilli, Mauro, et al.
Publicado: (2014)

Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine
por: Jasu, Juho, et al.
Publicado: (2021)

Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kaapu, Kalle J, et al.
Publicado: (2016)

Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kinnunen, Pete T. T., et al.
Publicado: (2017)

Antihypertensive drug use and prostate cancer-specific mortality in Finnish men
por: Siltari, Aino, et al.
Publicado: (2020)

Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time
por: Pylväläinen, Juho, et al.
Publicado: (2019)

Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system
por: Eskelinen, Tommi, et al.
Publicado: (2021)

Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level
por: Peltomaa, Antti I., et al.
Publicado: (2022)

The Importance of LDL and Cholesterol Metabolism for Prostate Epithelial Cell Growth
por: Murtola, Teemu J., et al.
Publicado: (2012)

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
por: Murtola, Teemu J., et al.
Publicado: (2018)

Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer
por: Ola, Idris Olasunmbo, et al.
Publicado: (2022)

Information Diversity in Structure and Dynamics of Simulated Neuronal Networks
por: Mäki-Marttunen, Tuomo, et al.
Publicado: (2011)

Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men
por: Kaapu, Kalle J., et al.
Publicado: (2018)

miR-32 promotes MYC-driven prostate cancer
por: Scaravilli, Mauro, et al.
Publicado: (2022)

DOT1L-HES6 fusion drives androgen independent growth in prostate cancer
por: Annala, Matti, et al.
Publicado: (2014)

Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial
por: Raittinen, Paavo V.H., et al.
Publicado: (2021)

Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer
por: Salminen, Jukka K., et al.
Publicado: (2022)

Information-Theoretic Analysis of the Dynamics of an Executable Biological Model
por: Sadot, Avital, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_op355b6ic7u2mbjjaq7e53c6lg